Anzeige
Mehr »
Login
Dienstag, 24.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 931150 | ISIN: NO0010000045 | Ticker-Symbol: PHS
Frankfurt
23.12.24
08:06 Uhr
5,340 Euro
+0,080
+1,52 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHOTOCURE ASA Chart 1 Jahr
5-Tage-Chart
PHOTOCURE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
5,3405,56023.12.
5,0805,13018.12.

Aktuelle News zur PHOTOCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoPhotocure ASA - Share option grant2
DoPhotocure ASA: Initiation of a share buyback2
12.12.Photocure ASA: Financial calendar2
03.12.Photocure ASA: Notification of primary insider transaction2
13.11.Photocure ASA reports Q3 results1
13.11.PHOTOCURE ASA Q3 Loss Declines3
PHOTOCURE Aktie jetzt für 0€ handeln
13.11.Photocure ASA: Results for the third quarter of 2024314OSLO, Norway, Nov. 13, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million)...
► Artikel lesen
06.11.Photocure ASA: Invitation to presentation of third quarter 2024 financial results-
05.11.Photocure ASA: Photocure Partner Asieris announces Marketing Approval by the National Medical Products Administration for Hexvix in China-
05.11.Photocure Partner Asieris announces Marketing Approval by the National Medical Products Administration for Hexvix in China1
30.09.Photocure ASA: Photocure Partner Asieris Unveils Cevira Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting4
30.09.Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting456OSLO, Norway, Sept. 30, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international...
► Artikel lesen
27.09.Photocure establishes Named Patient Program to provide access to Hexvix in South Africa366OSLO, Norway, Sept. 27, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part...
► Artikel lesen
27.09.Photocure ASA: Photocure establishes Named Patient Program to provide access to Hexvix in South Africa2
17.09.Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference675OSLO, Norway, Sept. 17, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today...
► Artikel lesen
17.09.Photocure ASA: Cevira: Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference4
16.09.Photocure ASA: Notification of major shareholding9
08.08.Photocure ASA reports Q2 results3
07.08.PHOTOCURE ASA Bottom Line Rises In Q2-
07.08.Photocure ASA: Results for the second quarter of 2024260OSLO, Norway, Aug. 7, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, today reported Hexvix®/Cysview® revenues of NOK 122.4 million in the second quarter of 2024...
► Artikel lesen
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1